Advanced Pancreatic Adenocarcinoma With Complete Response to Chemoimmunotherapy: A Case Report and Single‐Cell Profiling

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, especially in unresectable disease. We report a patient with metastatic PDAC who achieved durable complete remission after PD‐1 blockade combined with gemcitabine and albumin‐bound paclitaxel and remains disease‐free 4 years after diagnosis. To explore the immune basis of this response, we performed single‐cell RNA sequencing of peripheral blood mononuclear cells from seven patients receiving the same regimen. Responders showed enrichment of terminally differentiated CD8 + T (Temra) and CD4 ISG + T helper (Th) cells compared with nonresponders. Across independent cohorts, these two programs were positively correlated, suggesting coordinated immune activation during effective therapy. Predicted ligand–target interactions were linked to cytotoxic and immune activation pathways. These findings suggest that coordinated expansion of CD4 + ISG + Th and CD8 + Temra cells are associated with durable chemoimmunotherapy responses in PDAC and support peripheral blood immune profiling as a minimally invasive monitoring strategy. Trial Registration: ClinicalTrials.gov identifier: NCT05201729

Authors

Institutions

Publication Details

Journal
Cancer Science
Published
2026-11-20
DOI
https://doi.org/10.1111/cas.70599
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Advanced Pancreatic Adenocarcinoma With Complete Response to Chemoimmunotherapy: A Case Report and Single‐Cell Profiling

Taojing Ran, Duowu Zou, Xinchen Lu, Zonghao Liu et al.
Cancer Science
Pancreatic and Hepatic Oncology Research
article

Advanced Pancreatic Adenocarcinoma With Complete Response to Chemoimmunotherapy: A Case Report and Single‐Cell Profiling

Taojing Ran, Duowu Zou, Xinchen Lu, Zonghao Liu, ChenXiao Liu, Benyan Zhang, Lili Gao, Chunhua Zhou, Yao Zhang
article en

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, especially in unresectable disease. We report a patient with metastatic PDAC who achieved durable complete remission after PD‐1 blockade combined with gemcitabine and albumin‐bound paclitaxel and remains disease‐free 4 years after diagnosis. To explore the immune basis of this response, we performed single‐cell RNA sequencing of peripheral blood mononuclear cells from seven patients receiving the same regimen. Responders showed enrichment of terminally differentiated CD8 + T (Temra) and CD4 ISG + T helper (Th) cells compared with nonresponders. Across independent cohorts, these two programs were positively correlated, suggesting coordinated immune activation during effective therapy. Predicted ligand–target interactions were linked to cytotoxic and immune activation pathways. These findings suggest that coordinated expansion of CD4 + ISG + Th and CD8 + Temra cells are associated with durable chemoimmunotherapy responses in PDAC and support peripheral blood immune profiling as a minimally invasive monitoring strategy. Trial Registration: ClinicalTrials.gov identifier: NCT05201729

Cancer Science
Shanghai Jiao Tong University (CN), Ruijin Hospital (CN)
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon